GeoVax Labs, Inc. (Nasdaq: GOVX) today reported financial results for the second quarter ended June 30, 2026, and provided a business update emphasizing continued execution toward the planned initiation of a pivotal immunobridging study for its GEO-MVA vaccine candidate. The company is pursuing an expedited regulatory pathway established through formal Scientific Advice discussions with the European Medicines Agency (EMA).
During the quarter, GeoVax advanced multiple operational initiatives supporting the expected fourth-quarter start of the GEO-MVA study. These activities included clinical operations planning, start-up activities, utilization of previously manufactured cGMP clinical trial material, and advancement of the AGE1 continuous cell-line manufacturing platform for future commercial-scale production. The company also engaged with government, public health, and biodefense stakeholders regarding long-term orthopoxvirus preparedness and vaccine supply requirements.
“During the second quarter, we continued executing against what we believe is one of our most important value-creating milestones, as we prepare to initiate the pivotal GEO-MVA immunobridging study,” said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. “Our priorities remain clear: completing the activities necessary to initiate the study, maintaining disciplined capital allocation, and positioning GEO-MVA to address the growing global need for diversified MVA vaccine supply supporting public health preparedness and biodefense.”
GeoVax also continues advancing Gedeptin, its investigational gene-directed enzyme prodrug therapy (GDEPT), toward combination immunotherapy strategies designed to enhance immune checkpoint inhibitor activity in solid tumors. The company believes Gedeptin’s localized tumor-targeting mechanism and immune activation profile may complement PD-1-based therapies such as Merck’s Keytruda by improving responsiveness in immunologically resistant tumors. GeoVax maintains an exclusive intellectual property license from Emory University covering Gedeptin in combination with immune checkpoint inhibitors.
Financially, GeoVax reported a net loss of $4.4 million for the second quarter of 2026, or $0.97 per share, compared to a net loss of $5.4 million, or $8.74 per share, for the same period in 2025. For the six-month period, net loss was $9.7 million, or $2.94 per share, versus $10.7 million, or $19.72 per share, in the prior year. The company reported no revenue from government contracts in the 2026 periods, compared to $0.9 million and $2.5 million in the three- and six-month periods of 2025, respectively, reflecting the termination of a BARDA contract for the GEO-CM04S1 COVID-19 vaccine program in April 2025.
Research and development expenses decreased to $3.1 million for the quarter and $7.0 million for the six-month period, down from $4.7 million and $10.1 million in the comparable 2025 periods, primarily due to lower costs associated with discontinued BARDA contract activities and reduced GEO-CM04S1 clinical spending. General and administrative expenses were $1.3 million and $2.7 million for the three- and six-month periods, compared to $1.5 million and $3.2 million in 2025, reflecting lower investor relations consulting costs and reduced stock-based compensation.
As of June 30, 2026, GeoVax reported cash and cash equivalents of approximately $3.1 million, consistent with the $3.1 million at December 31, 2025. The company's strategic reprioritization in May 2026 focused resources on its lead programs, GEO-MVA and Gedeptin, while discontinuing active development of the GEO-CM04S1 COVID-19 vaccine candidate due to market contraction.
For more information, visit www.geovax.com.
